ArticleDiabetology & metabolic syndrome2026
Real-world comparative outcomes of atorvastatin, rosuvastatin, and lovastatin-niacin fixed-dose combination in metabolic dysfunction-associated steatotic liver disease: hepatic, metabolic, and economic perspectives.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a rising global health burden linked to dyslipidemia, metabolic syndrome, and hepatic inflammation. Statins are widely prescribed in MASLD, but comparative evidence on their efficacy, safety, and cost-effectiveness remains limited.
aimTo evaluate and compare the clinical effectiveness and cost-efficiency of atorvastatin, rosuvastatin, and lovastatin-niacin fixed-dose combination [LN-FDC; commercially distributed as Linicor in Taiwan] (lovastatin plus niacin) in improving liver enzymes and lipid profiles in MASLD patients.
methodsThis retrospective cohort study analyzed electronic medical records from a teaching hospital in southern Taiwan. Of 984 screened patients, 729 were included after 1:1 propensity score matching by age, sex, and baseline ALT. Patients received daily atorvastatin (20 mg), rosuvastatin (10 mg), or LN-FDC (20/500 mg) for six months. Primary outcomes were ALT and AST changes and treatment response (≥ 30% decline); secondary outcomes included lipid profiles, adverse events, and cost-effectiveness.
resultsAll three regimens were associated with statistically significant reductions in liver biochemistry and lipid markers over six months. LN-FDC was associated with the most substantial reductions in ALT and AST, with 53.5% achieving ≥ 30% AST decline versus < 30% with atorvastatin or rosuvastatin (p < 0.001). For ALT, LN-FDC was associated with a higher ALT response rate by six months (39.9% responders vs. ~31% in comparators, p = 0.048). While atorvastatin and rosuvastatin were associated with greater HDL-C improvements, LN-FDC was associated with decreased triglycerides and a low incremental cost-effectiveness ratio. Adverse events were infrequent but showed variation across groups. Specifically, Higher flush reactions were observed in LN-FDC patients, while higher gastrointestinal intolerance and liver enzyme elevations were shown in the atorvastatin group, and higher hyperglycemia was associated with rosuvastatin.
conclusionLN-FDC appeared to be associated with greater reductions and favorable cost patterns for improving hepatic inflammation and triglycerides in MASLD, though atorvastatin and rosuvastatin could increase HDL-C. Statin therapy thus provides dual hepatic and cardiovascular benefits in MASLD, with treatment choice guided by patient-specific metabolic and economic considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.